Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • herstein
    Junior Member
    • Oct 2011
    • 4

    #1

    Cufflinks 0 FPKM values

    Hi,

    We are running tophat/cufflinks on 3 identical human rna samples which were sequenced in 3 different lanes on 2 different flowcells. All 3 samples are from the exact same library.

    When running cufflinks, the genes.fpkm_tracking file for one sample is showing some genes with 0 FPKM and status FAIL, however these same genes in the other two samples are showing a non-zero FPKM.

    We are using tophat-1.4.0, bowtie-0.12.7, and cufflinks-1.3.0

    We ran tophat with the -G option and provided the gtf file. We ran cufflinks with -G option providing the same gtf file that we gave to tophat. We also ran cufflinks with -u -N --compatible-hits-norm -b hg19_ucsc.fa

    We've tried running without options -N and --compatible-hits-norm but still had the same results.

    We are confused how with 3 identical samples, one shows up with 0 FPKM but the other two seem to have valid FPKM's. For the 0-FPKM gene, we checked the bam file in IGV and it is definitely mapped.

    Has anyone encountered a similar problem or does anyone have any insight into this?

    Thanks!
    --Jennifer
  • letusgo
    Member
    • Aug 2011
    • 17

    #2
    Hi,
    Have you solved this problem yet? I met the same problem now.

    Comment

    • jp.
      Senior Member
      • Jul 2013
      • 142

      #3
      I also have same problem. I got only few genes with 0 FPKM value.
      I mean, control vs treated; control has 0 FPKM but treated shows 1098.13 FPKM.
      Theoretically speaking, it has very high fold increase, but cuffdiff Inf ?????
      do I have to include it or exclude. I think, this is very significant expression ????
      Can you all tell me please ?

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
        by SEQadmin2



        CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

        Despite this, “CRISPR helped turn genome editing from a specialized technique into
        ...
        07-31-2026, 11:01 AM
      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 08-06-2026, 07:41 AM
      0 responses
      17 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 08-03-2026, 10:13 AM
      0 responses
      33 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-31-2026, 02:55 AM
      0 responses
      43 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      26 views
      0 reactions
      Last Post SEQadmin2  
      Working...